TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07282743: Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Sponsor: Sun Pharmaceutical Industries Limited · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 285 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT07282743 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07282743 Rescue Dossier →